695-P: Comparison of Inpatient Glycemic Control in Hybrid Closed-Loop vs. Sensor-Augmented Insulin Delivery Systems

Abstract

The hybrid closed-loop (HCL) insulin delivery system is at the forefront of continuous subcutaneous insulin infusion technology. However, to our knowledge, no studies to date have compared inpatient glycemic control between the HCL and non-HCL delivery systems of the HCL insulin pumps. We aim to compare the efficacy and safety of glycemic control between these two insulin delivery systems in the hospital setting. We are performing a prospective study on patients using a HCL insulin pump who are admitted to a non-critical care floor. We included patients who were ≥18 years of age, diagnosed with type 1 or type 2 diabetes, on a HCL insulin pump for more than 4 weeks, and admitted for ≥2 days. The primary outcome is the comparison of percentage of point of care blood glucose readings between 70 and 180 mg/dL in the HCL system versus the non-HCL system. Secondary outcomes include percentage of glucose readings >180 mg/dL and Here, we report preliminary findings of 9 patients using the non-HCL system and 4 patients using the HCL system (Table 1). In the HCL group, >70% of the time was spent in the target blood glucose range of 70-180 mg/dL, 180 mg/dL, and Disclosure Y. Tsushima: None. A. Iqbal: None. J. F. Bena: None. M. Lansang: Consultant; Self; Sanofi. Research Support; Self; Dexcom, Inc.